IVERIC bio (Nasdaq:ISEE) - Aktienkurs, Nachrichten und Analyse

ISEE Aktienübersicht

IVERIC bio, Inc., a biopharmaceutical company, focuses on the discovery and development of novel treatments for retinal diseases with unmet medical needs.

Über das Unternehmen

ISEE grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	2/6
Künftiges Wachstum	5/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	5/6
Dividenden	0/6

Belohnungen

68.2% unter unserer Schätzung des beizulegenden Zeitwerts gehandelt

Prognostiziertes Gewinnwachstum 59.04% pro Jahr

Risikoanalyse

Erzielt weniger als 1 Million USD an Einnahmen ($0)

Die Aktionäre wurden im vergangenen Jahr verwässert

IVERIC bio, Inc. Wettbewerber

Abcam

NasdaqGS:ABCM

US$5.5b

Krystal Biotech

NasdaqGS:KRYS

US$5.4b

Avidity Biosciences

NasdaqGM:RNA

US$4.9b

Madrigal Pharmaceuticals

NasdaqGS:MDGL

US$5.3b

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für IVERIC bio
Historische Aktienkurse
Aktueller Aktienkurs	US$39.95
52-Wochen-Hoch	US$39.99
52-Wochen-Tief	US$9.39
Beta	1.1
11 Monat Veränderung	4.91%
3 Monate Veränderung	39.10%
1 Jahr Veränderung	236.28%
33 Jahre Veränderung	791.74%
5 Jahre Veränderung	1,413.26%
Veränderung seit IPO	51.90%

Aktuelle Nachrichten und Updates

Recent updates

Iveric drives Apellis lower as Street reacts to Phase 3 data for GA candidate

Sep 06

IVERIC bio Q2 2022 Earnings Preview

Jul 25

Iveric bio pay DelSiTech €1.25M upfront to develop new formulations of eye disorder drug Zimura

Jul 05

IVERIC bio: A First Take

Jun 23

We're Hopeful That IVERIC bio (NASDAQ:ISEE) Will Use Its Cash Wisely

May 20

Here's Why We're Not Too Worried About IVERIC bio's (NASDAQ:ISEE) Cash Burn Situation

Feb 01

Here's Why We're Not Too Worried About IVERIC bio's (NASDAQ:ISEE) Cash Burn Situation

Jul 02

IVERIC bio discusses GATHER2 enrollment and retention updates and new GATHER1 post-hoc analyses

Jun 18

IVERIC bio EPS misses by $0.04

May 05

We're Hopeful That IVERIC bio (NASDAQ:ISEE) Will Use Its Cash Wisely

Mar 12

We Think IVERIC bio (NASDAQ:ISEE) Can Afford To Drive Business Growth

Nov 27

IVERIC bio EPS misses by $0.05

Nov 02

Aktionärsrenditen

	ISEE	US Biotechs	US Markt
7D	0.9%	2.8%	3.6%
1Y	236.3%	11.8%	20.3%

Rendite im Vergleich zur Industrie: ISEE übertraf die Branche US Biotechs, die im vergangenen Jahr eine Rendite von 7.4 erzielte.

Rendite vs. Markt: ISEE übertraf den Markt US, der im vergangenen Jahr eine Rendite von 25.6 erzielte.

Preisvolatilität

Is ISEE's price volatile compared to industry and market?
ISEE volatility
ISEE Average Weekly Movement	5.4%
Biotechs Industry Average Movement	10.6%
Market Average Movement	6.2%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	3.2%

Stabiler Aktienkurs: ISEEDer Aktienkurs des Unternehmens war in den letzten 3 Monaten unbeständig.

Volatilität im Zeitverlauf: ISEEDie wöchentliche Volatilität der Aktie ist im vergangenen Jahr von 13% auf 5% zurückgegangen.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
2007	163	Glenn Sblendorio	ivericbio.com

IVERIC bio, Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von IVERIC bio im Vergleich zum Marktanteil des Unternehmens?
ISEE grundlegende Statistiken
Marktanteil	US$5.51b
Gewinn(TTM)	-US$222.90m
Umsatz(TTM)	n/a

0.0x

Kurs-Umsatz-Verhältnis

-24.7x

Kurs-Gewinn-Verhältnis

Ist ISEE zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
ISEE Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$0
Kosten der Einnahmen	US$136.54m
Bruttogewinn	-US$136.54m
Sonstige Ausgaben	US$86.37m
Umsatz	-US$222.90m

Zuletzt gemeldete Gewinne

Mar 31, 2023

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-1.62
Bruttomarge	0.00%
Nettogewinnspanne	0.00%
Schulden/Eigenkapital-Verhältnis	20.3%

Wie hat sich ISEE auf lange Sicht entwickelt?

Historische Performance und Vergleiche

ISEE Aktienübersicht

Belohnungen

Risikoanalyse

IVERIC bio, Inc. Wettbewerber

NasdaqGS:ABCM

US$5.5b

NasdaqGS:KRYS

US$5.4b

NasdaqGM:RNA

US$4.9b

NasdaqGS:MDGL

US$5.3b

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

IVERIC bio, Inc. Announces Positive 24-Month Topline Results from Phase 3 Study of IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy

European Medicines Agency Accepts Iveric Bio's Marketing Authorization Application for Avacincaptad Pegol for Geographic Atrophy

Iveric Bio Receives U.S. FDA Approval for IZERVAY™ (avacincaptad pegol intravitreal solution), a New Treatment for Geographic Atrophy

IVERIC bio, Inc. Files Form 15

IVERIC bio, Inc.(NasdaqGS:ISEE) dropped from NASDAQ Composite Index

IVERIC bio's Common Stock Delisted from NASDAQ

Recent updates

IVERIC bio, Inc. Announces Positive 24-Month Topline Results from Phase 3 Study of IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy

European Medicines Agency Accepts Iveric Bio's Marketing Authorization Application for Avacincaptad Pegol for Geographic Atrophy

Iveric Bio Receives U.S. FDA Approval for IZERVAY™ (avacincaptad pegol intravitreal solution), a New Treatment for Geographic Atrophy

IVERIC bio, Inc. Files Form 15

IVERIC bio, Inc.(NasdaqGS:ISEE) dropped from NASDAQ Composite Index

IVERIC bio's Common Stock Delisted from NASDAQ

Senior VP & COO exercised options and sold US$730k worth of stock

Senior VP & COO notifies of intention to sell stock

Consensus EPS estimates fall by 12%

Forecast to breakeven in 2025

Senior VP exercised options and sold US$2.2m worth of stock

Price target increased by 10% to US$35.09

Forecast to breakeven in 2025

Senior VP notifies of intention to sell stock

Senior VP & COO exercised options and sold US$940k worth of stock

Consensus revenue estimates fall by 13%

Senior VP & COO exercised options and sold US$299k worth of stock

No longer forecast to breakeven

Senior VP & COO exercised options and sold US$314k worth of stock

IVERIC bio, Inc. Announces U.S. Food and Drug Administration Accepts New Drug Application for Avacincaptad Pegol for the Treatment of Geographic Atrophy

Senior VP & COO notifies of intention to sell stock

CEO & Director exercised options and sold US$350k worth of stock

Iveric Bio Announces the Addition of Pravin U. Dugel to Its Board of Directors

Forecast to breakeven in 2025

Iveric Bio, Inc. Announces Completion of Rolling NDA Submission to FDA for Avacincaptad Pegol for the Treatment of Geographic Atrophy

Senior VP & COO exercised options and sold US$259k worth of stock

Senior VP & COO exercised options to buy US$109k worth of stock.

IVERIC bio, Inc. has completed a Follow-on Equity Offering in the amount of $300.375 million.

President exercised options to buy US$179k worth of stock.

IVERIC bio, Inc. Announces FDA Has Granted Breakthrough Therapy Designation for Avacincaptad Pegol for Geographic Atrophy

Price target increased to US$30.17

Senior VP & COO exercised options and sold US$964k worth of stock

IVERIC bio, Inc. Announces Submission of First Part of NDA for Rolling Review of Avacincaptad Pegol for the Treatment of Geographic Atrophy

IVERIC bio, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Iveric Bio Announces Positive Topline Data from Zimura® Gather2 Phase 3 Clinical Trial in Geographic Atrophy

Price target increased to US$26.36

Iveric drives Apellis lower as Street reacts to Phase 3 data for GA candidate

Senior VP & Chief Commercial Officer exercised options and sold US$138k worth of stock

IVERIC bio Q2 2022 Earnings Preview

IVERIC bio, Inc. to Report Q2, 2022 Results on Jul 26, 2022

Iveric Bio Announces Post-Hoc Analysis from GATHER1 Clinical Trial of Zimura® At American Society of Retina Specialists Meeting

Insider exercised options and sold US$73k worth of stock

Iveric bio pay DelSiTech €1.25M upfront to develop new formulations of eye disorder drug Zimura

IVERIC bio, Inc.(NasdaqGS:ISEE) dropped from Russell Microcap Value Index

IVERIC bio: A First Take

Independent Director recently bought US$241k worth of stock

IVERIC bio, Inc. Announces Presentation of Post-Hoc Analysis At Macula Society from Gather1 Clinical Trial of Zimura® in Patients with Geographic Atrophy

We're Hopeful That IVERIC bio (NASDAQ:ISEE) Will Use Its Cash Wisely

Price target increased to US$24.38

IVERIC bio, Inc. Completes Retrospective Review of Choroidal Neovascularization

IVERIC bio, Inc., Annual General Meeting, May 12, 2022

Senior VP exercised options and sold US$261k worth of stock

Senior VP notifies of intention to sell stock

IVERIC bio, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Iveric Bio Announces Foveal Anatomy Post-Hoc Analysis from GATHER1 Clinical Trial of Zimura® in Patients with Geographic Atrophy

Here's Why We're Not Too Worried About IVERIC bio's (NASDAQ:ISEE) Cash Burn Situation

IVERIC bio, Inc. Announces in GATHER2, the Company's Phase 3 Clinical Trial Evaluating the Safety and Efficacy of Zimura (Avacincaptad Pegol) for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration

CEO & Director exercised options and sold US$882k worth of stock

CEO & Director exercised options and sold US$122k worth of stock

Erträge & Einnahmen